On Monday, Matador Resources Corporation (NYSE:MTDR)’s shares gained 10.42%, and closed at $25.54, after Matador Resources Corporation, declared that, subject to market conditions, it intends to offer $350 million of senior unsecured notes due 2023 in a private placement to eligible purchasers. Matador intends to use the net proceeds from the offering primarily to repay a portion of the outstanding borrowings under its revolving credit facility and the debt assumed in connection with the merger of Harvey E. Yates Corporation with and into Matador’s wholly-owned partner, to fund a portion of its future capital expenditures and for other general working capital needs.
The notes have not been registered under the Securities Act of 1933, as amended, or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state securities laws. The notes may be resold by the initial purchasers following Rule 144A and Regulation S under the Securities Act.
Matador is an independent energy corporation engaged in the exploration, development, production and attainment of oil and natural gas resources in the United States, with an emphasis on oil and natural gas shale and other unconventional plays.
Rowan Companies plc (NYSE:RDC)’s shares jumped 6.70%, and settled at $19.28, during the last trading session on Monday, after Rowan Companies, plans to report earnings for the three months ended March 31, 2015 on Wednesday, May 6, 2015, before the open of the financial markets in the United States. Following the earnings report, the Corporation will conduct a conference call at 10:00 a.m. Central Daylight Time to talk about its operating results. Interested parties can listen to the conference call by telephone or over the internet.
Rowan Companies plc provides offshore oil and gas contract drilling services. It operates a fleet of 30 self-elevating mobile offshore jack-up drilling units, in addition to 3 ultra-deepwater drill ships.
At the end of Monday’s trade, Precision Drilling Corporation (NYSE:PDS)’s shares climbed 6.24%, and closed at $6.98.
Precision Drilling Corporation, intends to release its 2015 first quarter results before the market opens on Monday, April 27, 2015 and has planned a conference call and webcast to start promptly at 12:00 Noon MT (2:00 p.m. ET) on the same day.
The conference call dial in numbers are 866-226-1793 or 416-340-2216.
Precision Drilling Corporation provides oil and natural gas drilling and related services and products. The corporation operates through two segments, Contract Drilling Services; and Completion and Production Services. The Contract Drilling Services segment offers onshore well drilling services to exploration and production companies in the oil and natural gas industry.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA), ended its Monday’s trading session with 6.06% gain, and closed at $2.10, after Synta Pharmaceuticals, declared the closing of its underwritten public offering of 25,300,000 shares of ordinary stock, counting 3,300,000 shares sold following the full exercise of the option to purchase additional shares formerly granted to the underwriters, at a public offering price of $1.75 per share. Gross proceeds to Synta are about $44.3 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Synta.
Jefferies LLC and Cowen and Corporation, LLC acted as joint book-running managers for the offering, and JMP Securities LLC and Roth Capital Partners, LLC acted as co-managers for the offering.
Synta Pharmaceuticals Corp., a biopharmaceutical corporation, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate comprises ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
